Last reviewed · How we verify

Ibuprofen Acid

Reckitt Benckiser Healthcare (UK) Limited · FDA-approved active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce the production of prostaglandins, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever reduction, Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis).

At a glance

Generic nameIbuprofen Acid
SponsorReckitt Benckiser Healthcare (UK) Limited
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1 and COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation
PhaseFDA-approved

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits both COX-1 and COX-2 enzymes. By blocking these enzymes, it reduces prostaglandin synthesis, which are key mediators of inflammation, pain signaling, and fever regulation. This mechanism makes it effective for mild to moderate pain and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: